&nbsp;

Aug 2023

Drug

pemetrexed

Other Name(s): Alimta®

Quick Link(s):

Apr 2023

Drug

arsenic trioxide

Other Name(s): Trisenox®

Quick Link(s):

Oct 2023

Drug

pomalidomide

Other Name(s): Pomalyst®

Quick Link(s):

Aug 2023

Drug

ponatinib

Other Name(s): Iclusig®

Quick Link(s):

Aug 2023

Regimen

PCV

Cancer Type:

Central Nervous System

Intent: Adjuvant, Curative, Palliative

Funding:

ODB - General Benefit

procarbazine

ODB - General Benefit

lomustine

Drugs Used:

Quick Link(s):

Regimen Monograph

Jan 2023

Regimen

AZCT

Cancer Type:

Hematologic,

Leukemia - Acute Myeloid (AML),

Myelodysplastic Syndrome (MDS),

Myeloproliferative Neoplasms (MPNs)

Intent: Palliative

Funding:

New Drug Funding Program

Azacitidine - Intermediate-2 and high-risk myelodysplastic syndrome (MDS)

New Drug Funding Program

Azacitidine - Acute Myeloid Leukemia (AML)

New Drug Funding Program

Azacitidine - Acute Myeloid Leukemia (AML) Greater Than 30% Blasts

Drugs Used:

azaCITIDine

Quick Link(s):

Regimen Monograph

Jul 2023

Regimen

PNTM

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

New Drug Funding Program

Panitumumab - Metastatic Colorectal Small Bowel or Appendiceal Cancer

Drugs Used:

PANitumumab

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

ALEM+RITU

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Drugs Used:

alemtuzumab (Compassionate),

riTUXimab (Unfunded)

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

PACL(W)+RAMU

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Ramucirumab - Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Drugs Used:

ramucirumab,

PACLitaxel

Quick Link(s):

Regimen Monograph

Mar 2023

Regimen

PNAT

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

ponatinib - For the treatment of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia, according to specific clinical criteria

Drugs Used:

ponatinib